Search Results - "Aboud, Karam"

Cytotoxic chemotherapy: clinical aspects by Aboud, Karam, Meissner, Magdalena, Ocen, Joanita, Jones, Rob

“…Chemotherapeutic drugs exert their effects by interfering with the processes involved in cell division. Their therapeutic use stems from their ability to cause…”
Get full text

Use of ctDNA in identifying an actionable BRAF mutation in stage 4 metastatic melanoma by Bennett, Charlotte, Morgan, Sian, Aboud, Karam, Frazer, Ricky Dylan

“…The identification of genetic variants in melanoma has enabled the development of targeted therapies. Under the National Institute for Health and Care…”
Get more information

Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2) by Spicer, James F., Pinato, David James, Forster, Martin, Joshua, Anthony M., Korolewicz, James, Aboud, Karam, Morton, Cienne, Liu, Jia (Jenny), Cosman, Rasha, Main, Nicola Jane, Le Meur, Julia, Paull, Jeremy, Edmondson, Stephanie Ruth, Jones, Robert Hugh

“…3004 Background: DEP CTX is a highly optimized dendrimer nanoparticle formulation of cabazitaxel that achieves sustained cytotoxic drug delivery to tumors via…”
Get full text

Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in advanced esophagogastric cancers in a phase 1/2 trial by Pinato, David James, Jones, Robert Hugh, Forster, Martin D., Joshua, Anthony M., Korolewicz, James, Benafif, Sarah, Aboud, Karam, Liu, Jia (Jenny), Cosman, Rasha, Paull, Jeremy, Fairley, Jacinth, Edmondson, Stephanie Ruth, Spicer, James F.

“…374 Background: There is a significant unmet need in esophagogastric cancers (EGC) due to limited effective treatments (Tx) and poor prognosis. Dendrimers are…”
Get full text